top of page

Scientific, Regulatory & Strategic Consulting Services For The Life Sciences Industry

We provide scientific evaluation and business case analysis for potential assets in multiple therapeutic areas including metabolic disease, cardiovascular, GI, respiratory, WH/reproductive health, oncology, inflammation/autoimmunity and immuno-oncology/IO 

At BioPoint Consulting, LLC, we help clients build contract work with CROs and academic units focused on drug development. We also help design preclinical studies, clinical development plans and review project proposals


 Services include project and vendor management, medical writing support and regulatory strategy

What's Your Story?  Let BioPoint Help You Tell It  
Specialized Consulting Services

How Can BioPoint Consulting Help You?

Focused, Expert Advice

Working With BioPoint Consulting

Our Services

Business Asset Evaluation

Scientific evaluation of business assets for in-licensing activities, evaluation and analysis of data sets, due diligence and business intelligence builds.  Services include growth market analysis and pitch deck presentations

Drug Discovery/Preclinical Development

Evaluation and recommendation of in vitro and in vivo animal models of human disease, pharmacology, toxicology, PK/PD, study design and protocol builds, target identification and report summaries.  Services include slide presentations plus conference poster synthesis

Medical Writing/Regulatory Strategy

Report generation, IND and IB synthesis, NDA/BLA builds, preIND summaries, regulatory responses, FDA, EMA, PDMA.  Strategy for biologics, small molecule, cellular therapeutics.  505b1, 505b2, 505j

Client reviews

"I had the pleasure of working with Matthew via his BioPoint Consulting service the past seven months. Matthew provided excellent scientific advice on quite a few due diligence assets in the cardiovascular/metabolism and immuno-oncology area. Matthew provided prompt reviews and detailed summary for all the projects sometimes with a turn around time of less than 24 hours. His interactions with external colleagues and collaborators was very professional and I always got a very positive response about his subject area expertise from my colleagues. Matthew, through his extensive network community provided excellent choices for conducting research based studies at CROs."

P. Patel, Chief Scientific Offcier, CinRx Pharma
bottom of page